What's Happening?
The use of GLP-1 drugs, primarily for weight loss, is impacting the consumer packaged goods (CPG) market by altering consumer preferences and spending habits. According to a report by OC&C Strategy Consultants, the penetration rate of GLP-1 drugs is expected
to rise from 12% to 15-18% by 2031, causing a shift in the mix of products consumers purchase. While the overall volume demand for food and beverages may see a slight annual decline, the composition of consumer baskets is changing, with a focus on protein, nutrient density, and fresh and functional categories. This shift is driven by GLP-1 users who are increasingly focused on weight loss rather than diabetes management, leading to changes in consumption patterns. The report highlights that users are cycling on and off the drugs, which affects their purchasing behavior. As a result, CPG manufacturers are adapting by reshaping their portfolios, as seen in Danone's acquisition of Huel, a protein company, to align with these trends.
Why It's Important?
The growing use of GLP-1 drugs is significant for the CPG industry as it necessitates a strategic response to changing consumer demands. Companies are faced with the challenge of balancing volume sales with the need to cater to specific consumer groups seeking healthier options. This trend could lead to increased innovation in nutrient-dense products and smaller portion sizes, providing value to consumers focused on weight management. The shift in consumer spending away from indulgent categories like alcohol and sweet snacks towards healthier options such as prepared meats, yogurt, and seafood indicates a broader move towards health-conscious consumption. This change presents opportunities for CPG companies to capitalize on the demand for products that align with dietary guidance and nutritional needs.
What's Next?
As the penetration of GLP-1 drugs continues to grow, CPG companies are likely to further innovate and diversify their product offerings to meet evolving consumer preferences. This may involve developing new products with cleaner labels, stronger taste and texture, and reduced sugar and fat content. Companies will need to assess their portfolios to identify strengths and weaknesses and determine how best to address market demands. The competitive landscape may see varied approaches, with some companies focusing on acquisitions and others on enhancing their innovation pipelines. The ongoing cycling of GLP-1 users will require CPG manufacturers to remain agile in their strategies to cater to shifting consumer groups.
